

Genomic DNA from Vaccinia Virus, IHD

Catalog No. NR-2636

For research use only. Not for human use.

Contributor:
ATCC®

Product Description:

Genomic DNA was isolated from a preparation of cell lysate and supernatant from African green monkey cells (ATCC® CRL-2378.1™) infected with vaccinia virus, IHD (BEI Resources NR-52).

The IHD (International Health Division) strain was derived from the original New York City Board of Health (NYCBH) strain.¹ The IHD strain was propagated for many passages by intracerebral inoculation in mice and has similar virulence to the Western Reserve (WR) strain.^{1,2} It is being used in a lethal respiratory infection model in mice to evaluate antiviral compounds.² The coding sequences for several of the genes have been determined and are available in GenBank.

NR-2636 has been qualified for PCR applications by amplification of an approximately 2,600 bp sequence. NR-2636 is not intended for use as a standard for quantitative PCR.

Material Provided:

Each vial contains a target amount of 1×10^8 copies of viral genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) containing sodium azide. The actual number of copies per vial may vary from 10-fold lower to 10-fold higher. The number of copies per vial and the concentration are shown on the Certificate of Analysis. The viral genomic DNA is in a background of cellular nucleic acid and carrier RNA. The vial should be centrifuged prior to opening.

Packaging/Storage:

NR-2636 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Genomic DNA from Vaccinia Virus, IHD, NR-2636."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following

publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Parker, R. F., et al. "Further Studies of the Infectious Unit of Vaccinia." J. Exp. Med. 74 (1941): 263-281.
2. Smee, D. F., et al. "Effects of Four Antiviral Substances on Lethal Vaccinia Virus (IHD Strain) Respiratory Infections in Mice." Int. J. Antimicrob. Agents 23 (2004): 430-437. PubMed: 15120719.

ATCC® is a trademark of the American Type Culture Collection.



Biodefense and Emerging Infections Research Resources Repository

P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org